オピオイド使用障害の市場規模、シェア、動向分析レポート：薬物別、投与経路別、流通チャネル別、地域別、セグメント予測、2025年～2030年

オピオイド使用障害市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のオピオイド使用障害市場規模は2030年までに102億4,000万米ドルに達し、2025年から2030年までのCAGRは11.15％を示す見込みです。

オピオイド蔓延の増加と危機と闘うための政府のイニシアチブの高まりが市場成長を促進すると思われます。加えて、新規製品の商業化の拡大がさらに成長を促進すると予測されます。2018年、米国では15歳以上の約290万人がこの障害に苦しんでいました。2016年、米国薬物使用と健康に関する全国調査（NSDUH）によると、米国では前年に約1,150万人が処方薬オピオイドを乱用し、200万人以上が処方薬中毒でした。

CDCによれば、毎日約130人の米国人がオピオイドの過剰摂取により死亡しており、米国政府はこれを公衆衛生上の緊急事態と位置づけています。中毒を克服したい患者にとって、服薬支援治療（MAT）を順守することは、離脱症状を軽減し、死亡リスクを半減させることができます。米国FDAが承認したMATの選択肢は、ブプレノルフィン、メタドン、ナルトレキソンの3つです。ブプレノルフィンの連日経口投与が標準的な治療法です。

オピオイド危機と闘うために、近年いくつかの対策が講じられています。例えば、2016年には慢性疼痛に対してこれらの薬剤を処方するためのCDC臨床診療ガイドラインが発行され、2015年には標準治療を改善するための新しい米国中毒学会（ASAM）全国診療ガイドラインが採択されました。さらに2016年、米国FDAは乱用抑止オピオイドに関する規制を抜本的に見直し、安全性表示を強化し、使用のリスク・ベネフィット・パラダイムを再検討する計画を発表しました。

オピオイド使用障害市場レポート・ハイライト

• ブプレノルフィンは、オピオイド部分作動薬としての効果的な二重作用により市場をリードし、2024年の世界売上高の59.58%を占めます。
• 注射剤セグメントは市場を独占し、2024年の世界売上高の59.26％を占めました。ビビトロール（ナルトレキソン）やサブロケイド（ブプレノルフィン）のような徐放性注射剤は、長時間安定した薬物送達を提供し、服薬アドヒアランスを向上させ、再発リスクを低減します。
• 病院薬局は、複雑で重篤な症例の管理に不可欠な役割を担っているため、2024年の市場シェアは47.90%で市場を独占しています。
• 北米のオピオイド使用障害市場は、いくつかの重要な要因により、2024年に68.98%のシェアを占めました。同地域はOUDの有病率が最も高く、治療ソリューションに対する大きな需要を牽引しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 オピオイド使用障害市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• オピオイド使用障害市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 価格分析
• パイプライン分析
• 行動療法に関する定性分析

第4章 オピオイド使用障害市場分析、薬剤別

• 医薬品市場シェア、2024年と2030年
• セグメントダッシュボード
• 薬物展望による世界のオピオイド使用障害市場
• 2018年から2030年までの市場規模と予測および動向分析
  • ブプレノルフィン
  • メサドン
  • ナルトレキソン
  • その他

第5章 オピオイド使用障害市場分析、投与経路別

• オピオイド使用障害：投与経路の変動分析
• オピオイド使用障害市場分析、投与経路別市場
  • 経口投与
  • 注射剤投与
  • その他

第6章 オピオイド使用障害市場分析、流通チャネル別

• オピオイド使用障害：流通チャネルの変動分析
• オピオイド使用障害市場分析、流通チャネル市場別
  • 病院薬局
  • 小売薬局
  • その他

第7章 オピオイド使用障害市場：薬剤別、投与経路別、流通チャネル別の地域推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模と予測動向分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • Key customers
  • Key company market share analysis, 2024
  • Indivior PLC
  • Teva Pharmaceutical Industries, Ltd.
  • Pfizer, Inc.
  • BioDelivery Sciences International, Inc.（a part of Collegium Pharmaceutical, Inc.）
  • Genentech, Inc.（Roche）
  • Alkermes.
  • Orexo US Inc.（subsidiary of Orexo AB）
  • Titan Pharmaceuticals, Inc.
  • Omeros Corporation
  • Camurus AB
  • Hikma Pharmaceuticals PLC

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 4 Global opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 5 Global opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 North America opioid use disorder market, by region, 2018 - 2030 (USD Million)
• Table 7 North America opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 8 North America opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 9 North America opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 10 U.S. opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 11 U.S. opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 12 U.S. opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13 Canada opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 14 Canada opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 15 Canada opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 16 Mexico opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 17 Mexico opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Mexico opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 Europe opioid use disorder market, by country, 2018 - 2030 (USD Million)
• Table 20 Europe opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 21 Europe opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 22 Europe opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 23 UK opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 24 UK opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 25 UK opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 26 Germany opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 27 Germany opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 28 Germany opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 29 France opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 30 France opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 31 France opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 32 Italy opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 33 Italy opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 34 Italy opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 35 Spain opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 36 Spain opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 37 Spain opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 38 Norway opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 39 Norway opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 40 Norway opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 41 Sweden opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 42 Sweden opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Sweden opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 Denmark opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 45 Denmark opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 46 Denmark opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific opioid use disorder market, by country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 51 Japan opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 52 Japan opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 53 Japan opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54 China opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 55 China opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 56 China opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 57 India opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 58 India opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 59 India opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 60 Australia opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 61 Australia opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 62 Australia opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 63 South Korea opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 64 South Korea opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 65 South Korea opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 66 Thailand opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 67 Thailand opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 68 Thailand opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 Latin America opioid use disorder market, by country, 2018 - 2030 (USD Million)
• Table 70 Latin America opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 71 Latin America opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 72 Latin America opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 73 Brazil opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 74 Brazil opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 75 Brazil opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 76 Argentina opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 77 Argentina opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 78 Argentina opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa opioid use disorder market, by country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 83 South Africa opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 84 South Africa opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 85 South Africa opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 89 UAE opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 90 UAE opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 91 UAE opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)
• Table 92 Kuwait opioid use disorder market, by drug, 2018 - 2030 (USD Million)
• Table 93 Kuwait opioid use disorder market, by route of administration, 2018 - 2030 (USD Million)
• Table 94 Kuwait opioid use disorder market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Opioid use disorder market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Drug and route of administration segment snapshot
• Fig. 11 Distribution channel snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Global Pharmaceutical Market (USD Billion)
• Fig. 14 Market dynamics
• Fig. 15 Porter's five forces analysis
• Fig. 16 PESTLE analysis
• Fig. 17 Opioid use disorder: Drug outlook and key takeaways
• Fig. 18 Opioid use disorder market: Drug market movement analysis
• Fig. 19 Naltrexone market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Buprenorphine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 BELBUCA market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Sublocade market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Suboxone market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Zubsolv market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Other Buprenorphine products market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Methadone market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Opioid use disorder: Route of administration outlook and key takeaways
• Fig. 29 Opioid use disorder market: Route of administration market movement analysis
• Fig. 30 Oral administration market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Injectable administration market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Opioid use disorder: Distribution channel outlook and key takeaways
• Fig. 34 Opioid use disorder market: Distribution channel market movement analysis
• Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Opioid use disorder market revenue, by region, 2023 & 2030, USD Million
• Fig. 39 Regional marketplace: Key takeaways
• Fig. 40 North America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Key country dynamics
• Fig. 42 U.S. opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Key country dynamics
• Fig. 44 Canada opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Key country dynamics
• Fig. 46 Mexico opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Europe opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 UK opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Germany opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 France opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 Spain opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Key country dynamics
• Fig. 57 Italy opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 Denmark opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Sweden opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Norway opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Rest of Europe opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Key country dynamics
• Fig. 67 Japan opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 China opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 China regulatory details
• Fig. 71 India opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 Australia opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Key country dynamics
• Fig. 75 Thailand opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Key country dynamics
• Fig. 77 South Korea opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Rest of Asia Pacific opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Latin America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 Brazil opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Brazil regulation details
• Fig. 83 Key country dynamics
• Fig. 84 Argentina opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Argentina regulatory framework
• Fig. 86 Rest of Latin America opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 South Africa opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Key country dynamics
• Fig. 90 Saudi Arabia opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 Key country dynamics
• Fig. 92 UAE opioid use disorder market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Key country dynamics
• Fig. 94 Kuwait opioid use disorder market estimates and forecasts, 2018
• Fig. 95 Rest of MEA opioid use disorder market estimates and forecasts,
• Fig. 96 Company/competition categorization
• Fig. 97 Company market share analysis, 2024
• Fig. 98 Strategy mapping

Opioid Use Disorder Market Growth & Trends:

The global opioid use disorder market size is expected to reach USD 10.24 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 11.15% from 2025 to 2030. Rising opioid epidemic and growing government initiatives to combat the crisis are likely to propel market growth. In addition, growing commercialization of novel products is further anticipated to drive growth. In 2018, about 2.9 million people aged 15 or above were suffering from this disorder in the U.S. In 2016, according to the National Survey on Drug Use and Health (NSDUH), in the U.S., around 11.5 million people had abused prescription opioids in the earlier year and more than 2 million were addicted to prescribed drugs.

According to the CDC, around 130 Americans die every day due to the opioid overdose and the U.S. government has designated this as a public health emergency.For patients wanting to overcome their addiction, adherence to a Medication-assisted Treatment (MAT) can reduce the withdrawal symptoms and cut the risk of death by half. Three U.S. FDA-approved MAT options are buprenorphine, methadone, and naltrexone. They are available in numerous dosages and formulations, with daily oral buprenorphine as the standard of care.

To combat the opioid crisis, several measures have been undertaken in recent years. For instance, in 2016, CDC clinical practice guidelines for prescribing these drugs for chronic pain were issued and new American Society of Addiction Medicine (ASAM) National Practice Guidelines was adopted in 2015 to improve standard of care. Furthermore, in 2016, the U.S. FDA announced plans to overhaul its regulations for abuse-deterrent opioids, enhance safety labeling, and re-examine the risk-benefit paradigm of their use.

Opioid Use Disorder Market Report Highlights:

• Buprenorphine led the market and accounted for 59.58% of the global revenue in 2024 due to its effective dual action as a partial opioid agonist, which helps alleviate withdrawal symptoms and cravings while minimizing euphoria and misuse risk.
• The injectable segment dominated the market and accounted for 59.26% of the global revenue in 2024. Extended release injectables, like Vivitrol (naltrexone) and Sublocade (buprenorphine), offer prolonged, steady drug delivery, improving adherence and reducing the risk of relapse.
• Hospital pharmacies dominated the market with a market share of 47.90% in 2024 due to their integral role in managing complex and severe cases.
• North America opioid use disorder market accounted for 68.98% share in 2024 due to several key factors. The region has the highest prevalence of OUD, which drives significant demand for treatment solutions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary Distribution Channels
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Distribution Channels
• 1.9. List of Primary Distribution Channels
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug
  • 2.2.2. Route of Administration
  • 2.2.3. Distribution Channel
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Opioid Use Disorder Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising opioid epidemic
    • 3.2.1.2. Growing government initiatives to combat the crisis
    • 3.2.1.3. Growing awareness of opioid use disorder (OUD)
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Adverse effects associated to drug used for opioid treatment
    • 3.2.2.2. Complex reimbursement structure
• 3.3. Opioid Use Disorder Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis
• 3.5. Pipeline Analysis
• 3.6. Qualitative analysis about Behavioral Therapies

Chapter 4. Opioid Use Disorder Market Analysis, by Drug, 2018-2030 (USD Million)

• 4.1. Drug Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Opioid Use Disorder Market by Drug Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Buprenorphine
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Belbuca
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Suboxone
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Zubsolv
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Others
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Methadone
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Naltrexone
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Others
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Opioid Use Disorder Market Analysis, by Route of Administration, 2018-2030 (USD Million)

• 5.1. Opioid Use Disorder: Route of Administration Movement Analysis
• 5.2. Opioid Use Disorder Market Analysis, by Route of Administration Market (USD Million)
  • 5.2.1. Oral Administration
    • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 5.2.2. Injectable Administration
    • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 5.2.3. Others
    • 5.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 6. Opioid Use Disorder Market Analysis, by Distribution Channel, 2018-2030 (USD Million)

• 6.1. Opioid Use Disorder: Distribution Channel Movement Analysis
• 6.2. Opioid Use Disorder Market Analysis, by Distribution Channel Market (USD Million)
  • 6.2.1. Hospital Pharmacies
    • 6.2.1.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 6.2.2. Retail Pharmacies
    • 6.2.2.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)
  • 6.2.3. Others
    • 6.2.3.1. Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)

Chapter 7. Opioid Use Disorder Market: Regional Estimates and Trend Analysis by Drug, by Route of Administration, by Distribution Channel

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Indivior PLC
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Drug benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Teva Pharmaceutical Industries, Ltd.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Drug benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Pfizer, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Drug benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. BioDelivery Sciences International, Inc. (a part of Collegium Pharmaceutical, Inc.)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Drug benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Genentech, Inc. (Roche)
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Drug benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Alkermes.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Drug benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Orexo US Inc. (subsidiary of Orexo AB)
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Drug benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Titan Pharmaceuticals, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Drug benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Omeros Corporation
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Drug benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Camurus AB
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Drug benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Hikma Pharmaceuticals PLC
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Drug benchmarking
    • 8.3.14.4. Strategic initiatives